Literature DB >> 23058866

Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates.

Carolina Caballo1, Gines Escolar, Maribel Diaz-Ricart, Irene Lopez-Vílchez, Miguel Lozano, Joan Cid, Marcos Pino, Joan Beltrán, Misericordia Basora, Arturo Pereira, Ana M Galan.   

Abstract

BACKGROUND: Haemodilution during resuscitation after massive haemorrhage may worsen the coagulopathy and perpetuate bleeding.
MATERIALS AND METHODS: Blood samples from healthy donors were diluted (30 and-60%) using crystalloids (saline, Ringer's lactate, Plasmalyte(TM)) or colloids (6% hydroxyethylstarch [HES130/0.4], 5% human albumin, and gelatin). The effects of haemodilution on platelet adhesion (Impact R), thrombin generation (TG), and thromboelastometry (TEM) parameters were analysed as were the effects of fibrinogen, prothrombin complex concentrates (PCC), activated recombinant factor VII (FVIIa), and cryoprecipates on haemodilution.
RESULTS: Platelet interactions was already significantly reduced at 30% haemodilution. Platelet reactivity was not improved by addition of any of the concentrates tested. A decrease in TG and marked alterations of TEM parameters were noted at 60% haemodilution. HES130/0.4 was the expander with the most deleterious action. TG was significantly enhanced by PCC whereas rFVIIa only caused a mild acceleration of TG initiation. Fibrinogen restored the alterations of TEM parameters caused by haemodilution including those caused by HES 130/0.4. Cryoprecipitates significantly improved the alterations caused by haemodilution on TG and TEM parameters; the effects on TG disappeared after ultracentrifugation of the cryoprecipitates. DISCUSSION: The haemostatic alterations caused by haemodilution are multifactorial and affect both blood cells and coagulation. In our in vitro approach, HES 130/0.4 had the most deleterious effect on haemostasis parameters. Coagulation factor concentrates did not improve platelet interactions in the Impact R, but did have favourable effects on coagulation parameters measured by TG and TEM. Fibrinogen notably improved TEM parameters without increasing thrombin generation, suggesting that this concentrate may help to preserve blood clotting abilities during haemodilution without enhancing the prothrombotic risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23058866      PMCID: PMC3729130          DOI: 10.2450/2012.0034-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  35 in total

Review 1.  Management of massive blood loss: a template guideline.

Authors:  D Stainsby; S MacLennan; P J Hamilton
Journal:  Br J Anaesth       Date:  2000-09       Impact factor: 9.166

2.  The effects of margination and red cell augmented platelet diffusivity on platelet adhesion in complex flow.

Authors:  A Jordan; T David; S Homer-Vanniasinkam; A Graham; P Walker
Journal:  Biorheology       Date:  2004       Impact factor: 1.875

3.  An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation.

Authors:  Annabel Blasi; Joan Beltran; Arturo Pereira; Graciela Martinez-Palli; Abiguei Torrents; Jaume Balust; Elizabeth Zavala; Pilar Taura; Juan-Carlos Garcia-Valdecasas
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

4.  Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate.

Authors:  J N George; E B Pickett; R Heinz
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

5.  Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss.

Authors:  C R Valeri; G Cassidy; L E Pivacek; G Ragno; W Lieberthal; J P Crowley; S F Khuri; J Loscalzo
Journal:  Transfusion       Date:  2001-08       Impact factor: 3.157

6.  Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor.

Authors:  B Shenkman; N Savion; R Dardik; I Tamarin; D Varon
Journal:  Thromb Res       Date:  2000-08-15       Impact factor: 3.944

Review 7.  Thrombin generation assay and other universal tests for monitoring haemophilia therapy.

Authors:  K Váradi; P L Turecek; H P Schwarz
Journal:  Haemophilia       Date:  2004-09       Impact factor: 4.287

8.  Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients.

Authors:  G Escolar; M Garrido; R Mazzara; R Castillo; A Ordinas
Journal:  Transfusion       Date:  1988 Sep-Oct       Impact factor: 3.157

9.  Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.

Authors:  Pratima Chowdary; Pratima Chowdhury; Anton G Saayman; Ulrike Paulus; George P Findlay; Peter W Collins
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

10.  Recombinant FVIIa in the management of uncontrolled hemorrhage.

Authors:  Niamh M O'Connell; David J Perry; Andrew J Hodgson; Denise F O'Shaughnessy; Michael A Laffan; Owen P Smith
Journal:  Transfusion       Date:  2003-12       Impact factor: 3.157

View more
  11 in total

Review 1.  Reducing transfusion requirements in liver transplantation.

Authors:  Ciara I Donohue; Susan V Mallett
Journal:  World J Transplant       Date:  2015-12-24

2.  [Platelet function disorder in trauma patients, an underestimated problem? Results of a single center study].

Authors:  V Hofer; H Wrigge; A Wienke; G Hofmann; P Hilbert-Carius
Journal:  Anaesthesist       Date:  2019-05-16       Impact factor: 1.041

3.  Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.

Authors:  Henri M H Spronk; Till Braunschweig; Rolf Rossaint; Dirk C Wüst; Rene van Oerle; Brian Lauritzen; Rene Tolba; Oliver Grottke
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 4.  Hydroxyeyhyl starch: Controversies revisited.

Authors:  Rashmi Datta; Rajeev Nair; Anil Pandey; Nitish Gupta; Tapan Sahoo
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10

5.  Correction of hypothermic and dilutional coagulopathy with concentrates of fibrinogen and factor XIII: an in vitro study with ROTEM.

Authors:  Dag Winstedt; Owain D Thomas; Fredrik Nilsson; Knut Olanders; Ulf Schött
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-12-16       Impact factor: 2.953

6.  Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation.

Authors:  Lluis Pujadas-Mestres; Irene Lopez-Vilchez; Eduardo Arellano-Rodrigo; Joan Carles Reverter; Antonio Lopez-Farre; Maribel Diaz-Ricart; Juan Jose Badimon; Gines Escolar
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

7.  Clinical Significance of Detection of Coagulation Indexes, Immune Factors and Inflammatory Factors in Patients with Pregnancy-Induced Hypertension Syndrome in China.

Authors:  Fengmei Shi; Aijun Yu; Limei Yuan
Journal:  Iran J Public Health       Date:  2019-04       Impact factor: 1.429

Review 8.  Intravenous Fluid Administration and the Coagulation System.

Authors:  Corrin J Boyd; Benjamin M Brainard; Lisa Smart
Journal:  Front Vet Sci       Date:  2021-04-15

9.  Impact of Perioperative Massive Transfusion on Long Term Outcomes of Liver Transplantation: a Retrospective Cohort Study.

Authors:  Lingcan Tan; Xiaozhen Wei; Jianming Yue; Yaoxin Yang; Weiyi Zhang; Tao Zhu
Journal:  Int J Med Sci       Date:  2021-10-15       Impact factor: 3.738

10.  Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

Authors:  Gines Escolar; Victor Fernandez-Gallego; Eduardo Arellano-Rodrigo; Jaume Roquer; Joan Carles Reverter; Victoria Veronica Sanz; Patricia Molina; Irene Lopez-Vilchez; Maribel Diaz-Ricart; Ana Maria Galan
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.